Hu, J-c and Chai, X-q and Wang, D and Shu, S-h and Magnussen, CG and Xie, L-x and Hu, S-s, Intraoperative flurbiprofen treatment alters immune checkpoint expression in patients undergoing elective thoracoscopic resection of lung cancer, Medical Principles and Practice, 29, (2) pp. 150-159. ISSN 1011-7571 (2020) [Refereed Article]
Copyright 2019 The Author(s). Published by S. Karger AG, Basel This is an Open Access article licensed under the Creative Commons Attribution-NonCommercial-4.0 International License (CC BY-NC 4.0) https://creativecommons.org/licenses/by-nc/4.0/ Usage and distribution for commercial purposes requires written permission.
Materials and Methods: In this prospective double-blind trial, patients were randomized to receive intralipid (control group, n = 34, 0.1 mL/kg, i.v.) or flurbiprofen axetil (flurbiprofen group, n = 34, 50 mg, i.v.) before induction of anesthesia. PD-1 levels on T cell subsets, inflammation, and immune markers in peripheral blood were examined before the induction of anesthesia (T0) and 24 h (T1), 72 h (T2), and 1 week (T3) after surgery. A linear mixed model was used to determine whether the changes from baseline values (T0) between groups were significantly different.
Results: The increases in the percentage of PD-1(+)CD8(+) T cells observed at T1 and T2 in the control group were higher than those in the flurbiprofen group (T1: 12.91 ± 1.65 vs. 7.86 ± 5.71%, p = 0.031; T2: 11.54 ± 1.54 vs. 8.75 ± 1.73%, p = 0.004), whereas no differences were observed in the changes in the percentage of PD-1(+)CD4(+) T cells at T1 and T2 between the groups. Moreover, extensive changes in the percentage of lymphocyte subsets and inflammatory marker concentrations were observed at T1 and T2 after surgery and flurbiprofen attenuated most of these changes.
Conclusions: Perioperative administration of flurbiprofen attenuated the postoperative increase in PD-1 levels on CD8(+) T cells up to 72 h after surgery, but not after this duration. The clinical relevance of changes in PD-1 levels to long-term surgical outcome remains unknown.
|Item Type:||Refereed Article|
|Keywords:||flurbiprofen, immune cells, lung cancer, programmed death 1|
|Research Division:||Biomedical and Clinical Sciences|
|Research Group:||Oncology and carcinogenesis|
|Research Field:||Cancer therapy (excl. chemotherapy and radiation therapy)|
|Objective Group:||Clinical health|
|Objective Field:||Clinical health not elsewhere classified|
|UTAS Author:||Magnussen, CG (Associate Professor Costan Magnussen)|
|UTAS Author:||Hu, S-s (Miss Shanshan Hu)|
|Web of Science® Times Cited:||7|
|Deposited By:||Menzies Institute for Medical Research|
|Downloads:||13 View Download Statistics|
Repository Staff Only: item control page